ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
danny3
|
535 |
161K |
2 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
535
|
161K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
danny3
|
535 |
161K |
2 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
535
|
161K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
danny3
|
77 |
24K |
1 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
77
|
24K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
danny3
|
77 |
24K |
1 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
77
|
24K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
danny3
|
231 |
63K |
1 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
231
|
63K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Discussion
|
|
danny3
|
2.4K |
564K |
1 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
2.4K
|
564K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
Ann: Pause in Trading
|
|
danny3
|
52 |
10K |
3 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
52
|
10K
|
3
|
|
ASX - By Stock
|
CYC |
Re:
Ann: SNMMI Announcement Regarding USFDA Approval of Technegas
|
|
danny3
|
19 |
4.6K |
3 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
19
|
4.6K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
danny3
|
677 |
318K |
1 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
677
|
318K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Discussion
|
|
danny3
|
2.4K |
564K |
1 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
2.4K
|
564K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
FDA Approval
|
|
danny3
|
116 |
50K |
6 |
11/03/23 |
11/03/23 |
ASX - By Stock
|
116
|
50K
|
6
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Receives FDA Waiver for Pediatric Study Plan
|
|
danny3
|
40 |
15K |
3 |
26/04/21 |
26/04/21 |
ASX - By Stock
|
40
|
15K
|
3
|
|
ASX - By Stock
|
OPT |
Re:
Analyst Upgrade
|
|
danny3
|
88 |
47K |
2 |
24/01/21 |
24/01/21 |
ASX - By Stock
|
88
|
47K
|
2
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Ceasing to be a substantial holder
|
|
danny3
|
33 |
10K |
3 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
33
|
10K
|
3
|
|
ASX - By Stock
|
OPT |
Re:
News: OPT Opthea Priced IPO In U.S. Of 8.6 Million American Depositary Shares
|
|
danny3
|
10 |
7.1K |
0 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
10
|
7.1K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Announces Plans for Potential US listing and IPO
|
|
danny3
|
36 |
16K |
3 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
36
|
16K
|
3
|
|
ASX - By Stock
|
OPT |
Re:
Bell Potter includes OPT as pick for 2021
|
|
danny3
|
2 |
1.2K |
2 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
2
|
1.2K
|
2
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
|
|
danny3
|
124 |
51K |
2 |
11/06/20 |
11/06/20 |
ASX - By Stock
|
124
|
51K
|
2
|
|
ASX - By Stock
|
OPT |
Re:
explain the market cap
|
|
danny3
|
134 |
54K |
5 |
10/06/20 |
10/06/20 |
ASX - By Stock
|
134
|
54K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
News: CUV UPDATE 1-U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment
|
|
danny3
|
121 |
68K |
0 |
20/04/20 |
20/04/20 |
ASX - By Stock
|
121
|
68K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Published BNC210 Phase 2b Data, Additional Information
|
|
danny3
|
19 |
7.5K |
0 |
11/04/20 |
11/04/20 |
ASX - By Stock
|
19
|
7.5K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Published BNC210 Phase 2b Data, Additional Information
|
|
danny3
|
19 |
7.5K |
1 |
11/04/20 |
11/04/20 |
ASX - By Stock
|
19
|
7.5K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Trading Halt
|
|
danny3
|
9 |
4.4K |
1 |
21/11/19 |
21/11/19 |
ASX - By Stock
|
9
|
4.4K
|
1
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Chairman Address to the 2019 AGM
|
|
danny3
|
59 |
30K |
4 |
21/11/19 |
21/11/19 |
ASX - By Stock
|
59
|
30K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Ann: IMM presents positive interim phase 2 TACTI-002 data at SITC
|
|
danny3
|
30 |
18K |
0 |
08/11/19 |
08/11/19 |
ASX - By Stock
|
30
|
18K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Konekt agrees to and supports increased offer
|
|
danny3
|
5 |
2.6K |
3 |
07/11/19 |
07/11/19 |
ASX - By Stock
|
5
|
2.6K
|
3
|
|
ASX - By Stock
|
KKT |
Re:
franking credits
|
|
danny3
|
8 |
3.0K |
0 |
03/11/19 |
03/11/19 |
ASX - By Stock
|
8
|
3.0K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
franking credits
|
|
danny3
|
8 |
3.0K |
1 |
30/10/19 |
30/10/19 |
ASX - By Stock
|
8
|
3.0K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
franking credits
|
|
danny3
|
8 |
3.0K |
2 |
28/10/19 |
28/10/19 |
ASX - By Stock
|
8
|
3.0K
|
2
|
|
ASX - By Stock
|
KKT |
franking credits
|
|
danny3
|
8 |
3.0K |
0 |
28/10/19 |
28/10/19 |
ASX - By Stock
|
8
|
3.0K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
Title moderated
|
|
danny3
|
3 |
2.9K |
1 |
18/10/19 |
18/10/19 |
ASX - By Stock
|
3
|
2.9K
|
1
|
|
ASX - By Stock
|
OPT |
Re:
Is anyone else on here a Doctor or Biomedical researcher (etc)?
|
|
danny3
|
32 |
22K |
2 |
11/10/19 |
11/10/19 |
ASX - By Stock
|
32
|
22K
|
2
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Major Contract
|
|
danny3
|
17 |
7.4K |
4 |
08/10/19 |
08/10/19 |
ASX - By Stock
|
17
|
7.4K
|
4
|
|
ASX - By Stock
|
KKT |
Re:
Takeover offer
|
|
danny3
|
11 |
5.2K |
0 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
11
|
5.2K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
Takeover offer
|
|
danny3
|
11 |
5.2K |
0 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
11
|
5.2K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
price target
|
|
danny3
|
64 |
32K |
1 |
27/09/19 |
27/09/19 |
ASX - By Stock
|
64
|
32K
|
1
|
|
ASX - By Stock
|
OPT |
Re:
price target
|
|
danny3
|
64 |
32K |
5 |
17/09/19 |
17/09/19 |
ASX - By Stock
|
64
|
32K
|
5
|
|
ASX - By Stock
|
OPT |
Re:
Opthea Chart
|
|
danny3
|
307 |
164K |
2 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
307
|
164K
|
2
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
|
|
danny3
|
14 |
9.0K |
6 |
07/08/19 |
07/08/19 |
ASX - By Stock
|
14
|
9.0K
|
6
|
|
ASX - By Stock
|
KKT |
Re:
News: KKT Konekt Sees FY19 EBITDA Between $9.7 Mln And $9.9 Mln
|
|
danny3
|
6 |
4.5K |
1 |
23/07/19 |
23/07/19 |
ASX - By Stock
|
6
|
4.5K
|
1
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Ceasing to be a substantial holder
|
|
danny3
|
2 |
1.7K |
0 |
13/06/19 |
13/06/19 |
ASX - By Stock
|
2
|
1.7K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Strategic Review Outcome and Program Updates
|
|
danny3
|
21 |
8.9K |
0 |
29/05/19 |
29/05/19 |
ASX - By Stock
|
21
|
8.9K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Results of the PTSD Trial and Exposure Analyses Presented
|
|
danny3
|
2 |
2.3K |
1 |
21/05/19 |
21/05/19 |
ASX - By Stock
|
2
|
2.3K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Company Secretary Appointment/Resignation
|
|
danny3
|
15 |
5.3K |
5 |
13/05/19 |
13/05/19 |
ASX - By Stock
|
15
|
5.3K
|
5
|
|
ASX - By Stock
|
BNO |
Re:
Technicals looking sick
|
|
danny3
|
34 |
13K |
1 |
31/03/19 |
31/03/19 |
ASX - By Stock
|
34
|
13K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
Ann: KKT Half Year Investor Presentation
|
|
danny3
|
13 |
5.6K |
1 |
20/02/19 |
20/02/19 |
ASX - By Stock
|
13
|
5.6K
|
1
|
|
ASX - By Stock
|
BNO |
Re:
Capitulation time for Bionomics?
|
|
danny3
|
19 |
10K |
1 |
11/12/18 |
11/12/18 |
ASX - By Stock
|
19
|
10K
|
1
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Leadership Changes and Strategic Review
|
|
danny3
|
15 |
7.2K |
2 |
10/11/18 |
10/11/18 |
ASX - By Stock
|
15
|
7.2K
|
2
|
|
ASX - By Stock
|
KKT |
Re:
News: KKT Konekt Reports FY Underlying Revenue Of $89.1 Million
|
|
danny3
|
9 |
3.4K |
1 |
03/11/18 |
03/11/18 |
ASX - By Stock
|
9
|
3.4K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
lack of interest
|
|
danny3
|
9 |
3.6K |
0 |
31/10/18 |
31/10/18 |
ASX - By Stock
|
9
|
3.6K
|
0
|
|